T细胞型急性淋巴细胞白血病靶向治疗的研究进展  

Advances in targeted therapy of T-cell acute lymphoblastic leukemia

作　　者：王雪[1] 陈翀[1] 徐开林[1] 

机构地区：[1]徐州医学院附属医院血液科,221300

出　　处：《国际输血及血液学杂志》2015年第3期244-247,共4页International Journal of Blood Transfusion and Hematology

基　　金：国家自然科学基金资助项目（8100210,81272206）

摘　　要：T细胞型急性淋巴细胞白血病（T-ALL）为分子生物学特点与预后异质性大的恶性疾病,其侵袭性强,复发率高.尽管随着高强度联合化疗及造血干细胞移植（HSCT）应用于临床,T-ALL预后得到较大改善,但疗效仍不够理想.因此,深入研究T-ALL发病机制,探索新治疗靶位对于提高T-ALL疗效具有重要意义.随着对T-ALL分子生物学研究进展,T-ALL治疗的多个新型靶点被逐一发现.笔者拟就T-ALL靶向治疗新型靶点进行综述.T-cell acute lymphoblastic leukemia （T-ALL） is a malignant invasive disease which has high rate of relapse.Its molecular characterization and prognosis are characterized as high level of heterogeneity.With aggressive combined chemotheapy and hematopoietic stem cell transplantation （HSCT） applied to clinical,the prognosis of T-ALL has been improved,but the efficacy is not ideal.Therefore,further studies of T-ALL pathogenesis and explore new targeted therapy are of great significance for improving the efficacy of T-ALL.With advances in the molecular characterization of T-ALL,a mumber of new treatment targets were gradually discovered.This article reviews literature on the novel targets of T-ALL therapy.

关 键 词：白血病 T细胞 分子靶向治疗 受体 Notch1 磷脂酰肌醇3-激酶 细胞周期蛋白D 哺乳动物雷帕霉素靶蛋白 Bromo结构域 

分 类 号：R733.71[医药卫生—肿瘤]